Amylyx Pharmaceuticals (AMLX) Stock Forecast & Price Target

$1.97

+0.05 (+2.60%)

(As of 07/26/2024 ET)

Amylyx Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold
Based on 8 Analyst Ratings

Based on 8 Wall Street analysts who have issued ratings for Amylyx Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Hold." Out of the 8 analysts, 6 have given a hold rating, and 2 have given a buy rating for AMLX.

Consensus Price Target

$17.60
793.40% Upside

High Forecast	$37.00
Average Forecast	$17.60
Low Forecast	$3.00

According to the 8 analysts' twelve-month price targets for Amylyx Pharmaceuticals, the average price target is $17.60. The highest price target for AMLX is $37.00, while the lowest price target for AMLX is $3.00. The average price target represents a forecasted upside of 793.40% from the current price of $1.97.

Type	Current Forecast 7/28/23 to 7/27/24	1 Month Ago 6/28/23 to 6/27/24	3 Months Ago 4/29/23 to 4/28/24	1 Year Ago 7/28/22 to 7/28/23
Consensus Rating	Hold	Hold	Hold	Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	2 Buy rating(s)	2 Buy rating(s)	2 Buy rating(s)	6 Buy rating(s)
Hold	6 Hold rating(s)	6 Hold rating(s)	6 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$17.60	$24.80	$32.67	$49.50
Forecasted Upside	793.40% Upside	214.17% Upside	165.85% Upside	79.42% Upside

Get Amylyx Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter.

Ad American Hartford Gold Group

Prepare for a Recession Unlike Any Other

Dave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.

GET THE FREE GUIDE

AMLX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

AMLX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Amylyx Pharmaceuticals Stock vs. The Competition

Type	Amylyx Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.25	2.72	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	793.40% Upside	3,123.40% Upside	9.10% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
7/12/2024	The Goldman Sachs Group 2 of 5 stars		Boost Target	Neutral ➝ Neutral	$3.00 ➝ $4.00	+75.44%
7/10/2024	HC Wainwright 3 of 5 stars		Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00	+306.09%
5/14/2024	Mizuho 2 of 5 stars		Lower Target	Neutral ➝ Neutral	$4.00 ➝ $3.00	+64.83%
3/11/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Goodman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
3/11/2024	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
3/11/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Neutral
Get the Latest News and Ratings for AMLX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Amylyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
3/8/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ In-Line
12/12/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$36.00	+152.63%
6/26/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$53.00 ➝ $48.00	+108.15%
1/5/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$50.00	+40.69%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 06:49 AM ET.

AMLX Forecast - Frequently Asked Questions

What is Amylyx Pharmaceuticals' forecast for 2024?: According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Amylyx Pharmaceuticals is $17.60, with a high forecast of $37.00 and a low forecast of $3.00.
Should I buy or sell Amylyx Pharmaceuticals stock right now?: 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amylyx Pharmaceuticals in the last year. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AMLX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMLX, but not buy additional shares or sell existing shares.
Does Amylyx Pharmaceuticals's stock price have much upside?: According to analysts, Amylyx Pharmaceuticals's stock has a predicted upside of 184.84% based on their 12-month stock forecasts.
What analysts cover Amylyx Pharmaceuticals?: Amylyx Pharmaceuticals has been rated by research analysts at HC Wainwright, Mizuho, and The Goldman Sachs Group in the past 90 days.
Do Wall Street analysts like Amylyx Pharmaceuticals more than its competitors?: Analysts like Amylyx Pharmaceuticals less than other "medical" companies. The consensus rating for Amylyx Pharmaceuticals is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how AMLX compares to other companies.